Psychiatric side effects from topical ocular timolol, a beta-adrenergic blocker.

Abstract:

:Neuropsychiatric side effects have been reported with various systemic betablockers. Data submitted to the National Registry of Drug-Induced Ocular Side Effects appear to indicate similar adverse reactions secondary to topical ophthalmic timolol. One hundred sixty-three of 369 central nervous system cases (44%) reported depression, psychosis, confusion, and hallucinations following topical ophthalmic timolol administration. The psychiatric community should be aware that sudden changes in mental status or onset of common psychiatric conditions, such as depression, may be due to topical ocular timolol. Withdrawal of the drug usually results in disappearance of these effects in 1 to 7 days.

journal_name

J Clin Psychopharmacol

authors

Shore JH,Fraunfelder FT,Meyer SM

subject

Has Abstract

pub_date

1987-08-01 00:00:00

pages

264-7

issue

4

eissn

0271-0749

issn

1533-712X

journal_volume

7

pub_type

杂志文章
  • Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.

    abstract:PURPOSE/BACKGROUND:To add to limited evidence on the Abnormal Involuntary Movement Scale (AIMS) as a measure of tardive dyskinesia (TD) in clinical practice settings, the characteristics and correlates of AIMS scores were assessed. METHODS/PROCEDURES:Veterans with schizophrenia/schizoaffective, bipolar, or major depre...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000001229

    authors: Caroff SN,Leong SH,Roberts CB,Berkowitz RM,Campbell EC

    更新日期:2020-07-01 00:00:00

  • Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital Initiation: A Retrospective Cohort Study.

    abstract:PURPOSE:Long-acting injectable (LAI) antipsychotics are recommended especially for patients with multiple admissions and poor adherence. The empirical basis of this strategy is a matter of debate. METHODS:In a retrospective cohort study extending over 6 years, all patients admitted for inpatient treatment with a diagn...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0000000000000672

    authors: Rittmannsberger H,Rosenleitner J,Malsiner-Walli G,Werl R,Rittmannsberger B,Yazdi K

    更新日期:2017-04-01 00:00:00

  • Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.

    abstract::Quetiapine (QTP) combined with lithium (Li) or divalproex (DVP) for the treatment of mania was evaluated in 2 double-blind, placebo-controlled studies. Patients were randomized to 3 or 6 weeks of treatment with QTP plus Li/DVP or placebo (PBO) plus Li/DVP. Quetiapine was dosed up to 800 mg/d; Li was dosed to achieve s...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/01.jcp.0000144887.66319.2f

    authors: Yatham LN,Paulsson B,Mullen J,Vågerö AM

    更新日期:2004-12-01 00:00:00

  • Fluoxetine alters the effects of intravenous cocaine in humans.

    abstract::Fluoxetine, a selective serotonin reuptake inhibitor, is currently being evaluated as a potential treatment for cocaine abuse. This 4-week inpatient study evaluated the pharmacologic interaction between fluoxetine and cocaine in healthy adult male volunteers (N = 5) with histories of cocaine abuse. Oral capsules were ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Walsh SL,Preston KL,Sullivan JT,Fromme R,Bigelow GE

    更新日期:1994-12-01 00:00:00

  • Predictors for starting depot administration of risperidone in chronic users of antipsychotics.

    abstract:BACKGROUND:Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparison...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/JCP.0b013e31818a6d10

    authors: Vehof J,Postma MJ,Bruggeman R,De Jong-Van Den Berg LT,Van Den Berg PB,Stolk RP,Burger H

    更新日期:2008-12-01 00:00:00

  • Clozapine reduces water-drinking behavior in schizophrenic patients with polydipsia.

    abstract::Disordered water balance, or polydipsia, is an underassessed and underreported phenomenon present in the severely psychiatrically disabled population. Prevalence rates for polydipsia range from 6.2 to 20%. We followed up five male patients (mean age 43) with chronic schizophrenia who met the Kane criteria for being tr...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-199608000-00010

    authors: Fuller MA,Jurjus G,Kwon K,Konicki PE,Jaskiw GE

    更新日期:1996-08-01 00:00:00

  • Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment.

    abstract::This study investigated the effects of antidepressant treatment on platelet activation in depressed patients with ischemic heart disease (IHD). Plasma levels of platelet alpha-granule release products beta-thromboglobulin (BTG) and platelet factor 4 (PF4) were measured in 17 depressed patients with IHD who were treate...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200004000-00004

    authors: Pollock BG,Laghrissi-Thode F,Wagner WR

    更新日期:2000-04-01 00:00:00

  • Alprazolam treatment of postcoronary bypass anxiety and depression.

    abstract::The effectiveness of alprazolam in treating symptoms of anxiety and depression in 60 patients undergoing coronary bypass surgery was assessed in a double-blind, placebo-controlled study. The results indicate that alprazolam treatment for anxiety following coronary bypass surgery, particularly symptoms occurring in the...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Freeman AM 3rd,Fleece L,Folks DG,Sokol RS,Hall KR,Pacifico AD,McGiffin DC,Kirklin JK,Zorn GL,Karp RB

    更新日期:1986-02-01 00:00:00

  • Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study.

    abstract::The objective of this study was to investigate the efficacy of pirenzepine in the treatment of clozapine-induced hypersalivation. Pirenzepine is reported to counteract hypersalivation by its selective antagonistic activity on the M4-muscarinic receptor, which is stimulated by clozapine. Twenty patients with clozapine-...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200112000-00012

    authors: Bai YM,Lin CC,Chen JY,Liu WC

    更新日期:2001-12-01 00:00:00

  • α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.

    abstract:PURPOSE:The aim of this article is to review the recent trials of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists and positive allosteric modulators (PAMs) on the treatment of cognitive decline in schizophrenia. α7 Nicotinic acetylcholine receptor abnormalities in schizophrenia and clinical implications of α7 n...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/JCP.0000000000000859

    authors: Jones C

    更新日期:2018-06-01 00:00:00

  • Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study.

    abstract:BACKGROUND:Several lines of evidence implicate glutamatergic neurotransmission in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine is an endogenous antagonist of glycine transporter-1. By blocking glycine uptake, sarcosine may increase the availability of synaptic glycine and enhance N-methyl-d-asp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0b013e3182189878

    authors: Wu PL,Tang HS,Lane HY,Tsai CA,Tsai GE

    更新日期:2011-06-01 00:00:00

  • The pharmacologic treatment of neuroleptic-induced akathisia.

    abstract::Akathisia is a frequent and distressing side effect of neuroleptic medications. The literature regarding the pharmacologic treatment of acute neuroleptic-induced akathisia is critically reviewed, including nine reports of the use of anticholinergic agents, 15 of the use of beta-blocking agents, and six of the use of b...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00004714-199002000-00003

    authors: Fleischhacker WW,Roth SD,Kane JM

    更新日期:1990-02-01 00:00:00

  • Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.

    abstract:BACKGROUND:Some studies have shown that low dose of neuroleptic addition to ongoing antiobsessive treatment might be effective in treatment resistant obsessive-compulsive disorder (OCD). The primary purpose of this study was to evaluate the efficacy of low-dose quetiapine in clomipramine and serotonin reuptake inhibito...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.jcp.0000088900.24613.f2

    authors: Sevincok L,Topuz A

    更新日期:2003-10-01 00:00:00

  • Clinical Risk Factors for Therapeutic Lithium-Associated Electrocardiographic Changes in Patients With Bipolar Disorder.

    abstract:PURPOSE/BACKGROUND:Lithium, a common medication used in bipolar disorder treatment, can exert an inhibitory effect on sodium and potassium channels and potentially cause cardiac electrical conduction disturbance and corrected QT (QTc) prolongation. This study aimed to examine whether lithium at therapeutic levels can c...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1097/JCP.0000000000001164

    authors: Chen PH,Kao YH,Chang CK,Lin YK,Lin YF,Chen YJ

    更新日期:2020-01-01 00:00:00

  • Evaluation of the effects of duloxetine and escitalopram on 24-hour heart rate variability: a mechanistic study using heart rate variability as a pharmacodynamic measure.

    abstract::A decrease in heart rate variability (HRV) can indicate increased sympathetic nervous system activity and possibly increased norepinephrine levels. In this randomized, placebo- and escitalopram (ESC)-controlled, subject-blind, 2-period, crossover study, 26 healthy subjects 50 to 65 years old received duloxetine (DLX) ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e31828567b6

    authors: Chappell JC,Kovacs R,Haber H,Wright R,Mitchell MI,Detke M,Pangallo B

    更新日期:2013-04-01 00:00:00

  • Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.

    abstract::The objective of this study was to compare the efficacy of the alpha-2a agonist guanfacine with that of dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD). Seventeen adult outpatients who met DSM-IV criteria for ADHD participated in a double-blind, placebo-controlled, crossove...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200104000-00015

    authors: Taylor FB,Russo J

    更新日期:2001-04-01 00:00:00

  • Tiaspirone in schizophrenia.

    abstract::It was predicted that tiaspirone, a novel compound, would benefit schizophrenic patients since in animal experiments it is a potent dopamine blocker. Following a placebo washout period of 1 to 2 weeks, 14 patients were treated for 28 days with the drug in a single-blind, dose ranging trial. GAS, NOSIE, and BPRS scores...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Moore NC,Meyendorff E,Yeragani V,LeWitt PA,Gershon S

    更新日期:1987-04-01 00:00:00

  • The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.

    abstract::In this study, the authors investigated the relationship between the metabolism of clomipramine (C) and the genotypes of cytochrome P450 (CYP) CYP2C19 and CYP2D6. Fifty-one Japanese patients (18 men and 33 women) were administered 10 to 250 mg/day of C by mouth and maintained on the same daily dose of C for at least 2...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004714-200112000-00002

    authors: Yokono A,Morita S,Someya T,Hirokane G,Okawa M,Shimoda K

    更新日期:2001-12-01 00:00:00

  • Treatment-resistant catatonic stupor and combined lithium-neuroleptic therapy: a case report.

    abstract::A case of treatment-resistant catatonic stupor responding to combined lithium-neuroleptic medications is described. As there are no reports in the literature of combined lithium-neuroleptic medications being effective for this potentially life-threatening disorder, the course of recovery is detailed and the risks and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Climo LH

    更新日期:1985-06-01 00:00:00

  • The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.

    abstract::The clinician using neuroleptic drugs for the treatment of psychotic patients must face a number of questions regarding whether and how to use anticholinergic drugs when extrapyramidal side effects appear. This article explores some of these questions, suggests how they might best be answered, reviews the studies whic...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: McEvoy JP

    更新日期:1983-10-01 00:00:00

  • Benzodiazepine-receptor ligands in humans: acute performance-impairing, subject-rated and observer-rated effects.

    abstract::The study presented here compared the acute performance-impairing, subject-rated, and observer-rated effects of quazepam (15, 30, and 45 mg), triazolam (0.1875, 0.375, and 0.5625 mg), zolpidem (7.5, 15, and 22.5 mg), and placebo in nine healthy, non-drug-abusing humans. Quazepam, a trifluoroethylbenzodiazepine, was ch...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199804000-00008

    authors: Rush CR,Armstrong DL,Ali JA,Pazzaglia PJ

    更新日期:1998-04-01 00:00:00

  • Prior Antidepressant Treatment Trials May Predict a Greater Risk of Depressive Relapse During Antidepressant Maintenance Therapy.

    abstract:BACKGROUND:We examined the influence of prior antidepressant treatment trials on the likelihood of depressive relapse, and time to depressive relapse, during maintenance therapy of bipolar II disorder in treatment-responsive subjects who had recovered from a major depressive episode. METHODS:Data were derived from a p...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/JCP.0000000000001049

    authors: Amsterdam JD,Kim TT

    更新日期:2019-07-01 00:00:00

  • A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.

    abstract::Although recent treatment guidelines for schizophrenia recommend that the prior antipsychotic agent should remain stable for at least 2 weeks when aripiprazole is introduced, there is no trial-based evidence to support this strategy. This study was designed to compare this strategy with another conventional one in pat...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/JCP.0b013e3181842586

    authors: Takeuchi H,Suzuki T,Uchida H,Nakajima S,Nomura K,Kikuchi T,Manki H,Watanabe K,Kashima H

    更新日期:2008-10-01 00:00:00

  • Trends in the adoption of medications for alcohol dependence.

    abstract::Increasing attention is being paid to the development and dissemination of effective pharmacotherapies for the treatment of alcohol and other drug dependence. However, numerous structural and philosophical barriers impede the widespread adoption of these treatment approaches in everyday clinical practice. Research is ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1097/01.jcp.0000246209.18777.14

    authors: Ducharme LJ,Knudsen HK,Roman PM

    更新日期:2006-12-01 00:00:00

  • Coadministration of fluvoxamine increases serum concentrations of haloperidol.

    abstract::Four patients with chronic schizophrenia were treated with a combination of fluvoxamine, haloperidol, and benztropine. The combination significantly impaired performance on tests of delayed recall memory and attentional function. Haloperidol concentrations in serum were monitored in three patients and were robustly el...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Daniel DG,Randolph C,Jaskiw G,Handel S,Williams T,Abi-Dargham A,Shoaf S,Egan M,Elkashef A,Liboff S

    更新日期:1994-10-01 00:00:00

  • A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.

    abstract::In a multicenter study of 78 severely depressed inpatients (44 women and 34 men; age range, 23 to 70 years), the efficacy, onset of efficacy, and tolerability of the reversible monoamine oxidase-A inhibitor moclobemide (450 mg/day) in combination with thioridazine (100 mg/day) were compared with those of moclobemide (...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-199508001-00008

    authors: Stabl M,Kasas A,Blajev B,Bajetta G,Zöchling R,Holsboer-Trachsler E,Realini R,Schäublin-Loidl M

    更新日期:1995-08-01 00:00:00

  • Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

    abstract::Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200006000-00007

    authors: Troy SM,Lucki I,Unruh MA,Cevallos WH,Leister CA,Martin PT,Furlan PM,Mangano R

    更新日期:2000-06-01 00:00:00

  • Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

    abstract::This 6-week, double-blind, placebo-controlled study evaluated paliperidone extended-release (ER) as both monotherapy and adjunctive therapy to mood stabilizers and/or antidepressants (MS/ADs) for schizoaffective disorder. Included subjects had a schizoaffective disorder diagnosis; a Positive and Negative Syndrome Scal...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/JCP.0b013e3181eeb600

    authors: Canuso CM,Schooler N,Carothers J,Turkoz I,Kosik-Gonzalez C,Bossie CA,Walling D,Lindenmayer JP

    更新日期:2010-10-01 00:00:00

  • Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness.

    abstract::This study tested the association between tardive dyskinesia (TD) and polymorphic variations in (a) 2 cytochrome P450 (CYP) genes (CYP2D6 or CYP3A5), (b) 2 DRD2 variants (Ser311Cys and -141C Ins/del) and the Ser9Gly DRD3 variants, (c) 2 glutathione S-transferases (GSTT1 and GSTM1), and (d) variations in the PgP gene, ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.jcp.0000177546.34799.af

    authors: de Leon J,Susce MT,Pan RM,Koch WH,Wedlund PJ

    更新日期:2005-10-01 00:00:00

  • Duration of imipramine therapy and relapse in panic disorder with agoraphobia.

    abstract::It has been suggested that maintenance treatment of patients who have remitted panic disorder with agoraphobia beyond the six months of acute phase imipramine treatment may decrease the risk of relapse. This study further explores the relationship between relapse and duration of imipramine treatment in this population...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004714-200206000-00010

    authors: Mavissakalian MR,Perel JM

    更新日期:2002-06-01 00:00:00